Alpha Teknova (TKNO) Non-Current Deffered Revenue (2020 - 2021)
Alpha Teknova (TKNO) posted quarterly Non-Current Deffered Revenue of $269000.0 for Q4 2021, up 31.86% year-over-year from $204000.0 in Q4 2020, and up 1.89% quarter-over-quarter from $264000.0 in Q3 2021.
Alpha Teknova (TKNO) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Alpha Teknova (TKNO) has reported Non-Current Deffered Revenue for 2 consecutive years, with $269000.0 the latest figure, recorded in Q4 2021.
- In Q4 2021, Non-Current Deffered Revenue rose 31.86% year-over-year to $269000.0; the TTM figure through Dec 2021 stood at $269000.0 (up 31.86% YoY), while the FY2021 annual figure was $269000.0, up 31.86% from the prior year.
- Non-Current Deffered Revenue grew to $269000.0 in Q4 2021 per TKNO's latest filing, from $264000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $269000.0 in Q4 2021 and bottomed at $204000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alpha Teknova | 396.90 Mn | 379.46 Mn | 4.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 269,000.00 |
| Sep 30, 2021 | 264,000.00 |
| Jun 30, 2021 | 253,000.00 |
| Dec 31, 2020 | 204,000.00 |